Insys Therapeutics (INSY) shares have edged higher in pre-market trading today after the company announced that the first patient has been enrolled in a Phase 2 study evaluating its pharmaceutical cannabidiol candidate for the treatment of cocaine dependence. The primary endpoint is drug-cue-induced craving at Day 8 as measured by a 10-point visual analog scale (VAS). Secondary endpoints are stress-induced craving at Day 8, cocaine use during the post-detoxification phase and the number of days to relapse. The study is expected to be completed by December 2019.